Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Video Expert Opinion
Colleague Insights
Conferences
Sign in
Join now
story of the week
Published in Multiple Sclerosis and
1 other channel

Journal Scan / Research · November 27, 2023

Yet Another Study Supporting Extended-Interval Ocrelizumab Dosing in Patients With MS

Multiple Sclerosis (Houndmills, Basingstoke, England)

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Ahmed Obeidat MD, PhD

Multiple Sclerosis (Houndmills, Basingstoke, England)
Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity
Mult. Scler. 2023 Nov 09;[EPub Ahead of Print], N Bou Rjeily, KC Fitzgerald, EM Mowry

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated